ArticleVaccine2019
A social justice perspective on access to human rabies vaccines.
Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Healthcare accessibility to rabies post-exposure prophylaxis in rural Kenya: implications for vaccine placement and travel time.Frontiers in microbiology · 2026Article
- Practitioner's perspectives on access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practice.PLOS global public health · 2026Article
- Towards "Zero by 30", the Kenyan case: a systematic exploration of barriers to rabies policy implementation through systems thinking.Health research policy and systems · 2025Article
- Access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practise.medRxiv : the preprint server for health sciences · 2025Article
- Disparities in Global Rabies Burden from GBD 2021: Children, older adults, and low-SDI countries at continued risk.PLoS neglected tropical diseases · 2025Article
- Changes in feral dog populations during the COVID-19 pandemic in Arequipa, Peru.Frontiers in veterinary science · 2025Article
- Molecular characterisation of human rabies in Tanzania and Kenya: a case series report and phylogenetic investigation.Infectious diseases of poverty · 2024Article
- Rabies post-exposure prophylaxis delivery to ensure treatment efficacy and increase compliance.IJID one health · 2023Article
- Comparative Evaluation of IntradermalVaccines · 2023Article
- Impact of the switch from four to three intradermal rabies post-exposure prophylaxis sessions in patients bitten by dogs: A cost-consequence analysis from the patients' perspective.One health (Amsterdam, Netherlands) · 2022Article
- Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.European journal of medicinal chemistry · 2022Article
- Rabies Elimination in Rural Kenya: Need for Improved Availability of Human Vaccines, Awareness and Knowledge on Rabies and Its Management Among Healthcare Workers.Frontiers in public health · 2022Article
- Vaccine manufacturing capacity in low- and middle-income countries.Bulletin of the World Health Organization · 2021Article
- How geographic access to care shapes disease burden: The current impact of post-exposure prophylaxis and potential for expanded access to prevent human rabies deaths in Madagascar.PLoS neglected tropical diseases · 2021Article
- Using data-driven approaches to improve delivery of animal health care interventions for public health.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Human rabies: prospects for elimination.CAB reviews : perspectives in agriculture, veterinary science, nutrition and natural resources · 2021Article
- [New aspects of rabies control].Bulletin de l'Academie nationale de medecine · 2020Review
- Rabies as a Public Health Concern in India-A Historical Perspective.Tropical medicine and infectious disease · 2020Review
- Behavioral and structural barriers to accessing human post-exposure prophylaxis and other preventive practices in Arequipa, Peru, during a canine rabies epidemic.PLoS neglected tropical diseases · 2020Article
- Zero human deaths from dog-mediated rabies by 2030: perspectives from quantitative and mathematical modelling.Gates open research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Rabies kills tens of thousands of people every year despite being entirely vaccine preventable. Key global health actors have launched a country-driven plan to achieve zero human deaths from dog-mediated rabies by 2030 worldwide. This partnership has recently been strengthened by Gavi, the Vaccine Alliance's decision to invest in human rabies vaccines for post-exposure prophylaxis (PEP). While nation states are key to rabies elimination, the importance of Gavi's role cannot be understated. Unlike any other actor, Gavi can directly address an otherwise intractable market failure in the inadequate supply of rabies PEP. In this commentary, we employ the Capabilities Approach to identify the barriers to PEP access that lead to this market failure and, as a result, unnecessary deaths and suffering. We show the role that Gavi can play in reducing exposure of PEP supply to market forces as a matter of social justice, and hence redress the inequity underlying human rabies deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.